Compare AbbVie Inc (ABBV) vs AT&T Inc. (T) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs AT&T Inc. — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while AT&T Inc. trades at $21.1 (market cap $146.54B). The key difference: AbbVie Inc is far larger — about 3.1× AT&T Inc.'s market cap, and AT&T Inc. pays the higher dividend (5.26%). Which is the better fit depends on your goals.
| ABBV | T | |
|---|---|---|
Market Cap | $449.91B | $146.54B |
Sector | Health | Media |
52-Week High | $261.07 | $29.62 |
52-Week Low | $184.85 | $20.49 |
Enterprise Value | $513.38B | $291.89B |
Dividend Yield | 2.72% | 5.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
AT&T (T) trades at $21.06, up 2.38% today but remains near multi-year lows amid competitive pressures. The stock shows bearish technical signals with key support at $20, while fundamentals reveal strong profitability with a 16.94% net margin and attractive valuation at a P/E of 6.93. Recent earnings beats and a 5.4% dividend yield provide support, but SpaceX competition concerns dominate sentiment.
Outlook: Undervalued with significant upside to the $29.50 consensus target, but high debt and Starlink disruption risks temper near-term optimism. Investment case hinges on execution in fiber/wireless growth against stiff competition, with cash flow stability supporting the dividend.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
